Live Breaking News & Updates on Regulatory Affairs At Red Cat

Stay updated with breaking news from Regulatory affairs at red cat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Insight Global to pay $2.7 million in whistleblower lawsuit

Insight Global LLC to pay $2.7 million to settle allegations in whistleblower lawsuit over covid-19 cybersecurity measures, the Department of Justice announced. ....

Pennsylvania , United-states , Florida , Terralyn-williams-seilkop , Us-department-of-justice , Insight-global , Pennsylvania-department-of-health , Department-of-justice , Google , Daily-newsview-all , Pennsylvania-department , False-claims-act

FDA wary of impact of retirements on inspectional activities

The U.S. FDA’s senior managers often lament the lack of routine increases in taxpayer funding, a concern that Michael Rogers, the associate FDA commissioner for regulatory affairs, reiterated during a May 1 webinar. Rogers said the agency’s field inspectorate will be working through a large number of retirements over the next few years, a predicament he said will continue to be “a huge challenge” to overcome. ....

Michael-rogers , Bioworld-medtech , Fda-office-of-regulatory-affairs , Fda-ora , Fda-oii , Alliance-fora-stronger-fda , Fda , Regulatory , Us ,

Since WHIM? Finally, targeted drug enters space from X4

X4 Pharmaceuticals Inc. is raring to go with marketing after the firm scored U.S. FDA approval of Xolremdi (mavorixafor) capsules for patients 12 years and older with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, to increase the number of circulating mature neutrophils and lymphocytes. ....

Pharmaceuticals-inc , X4-pharmaceuticals-inc , Xolremdi , Mavorixafor , Whim-syndrome , Cxcr4 , Bioworld , Regulatory , Us , Infection , Immune

FDA's final LDT rule prompts more calls for passage of VALID Act

The U.S. FDA has posted the long-awaited final rule for lab-developed tests, which amends the draft rule in a few key respects, but Reps. Diana DeGette and Larry Buchson, once again voiced their opposition to the rule. DeGette and Bucshon acknowledged that congressional inaction has left the FDA with few choices, but called again for passage of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act, which they said is critical because “burdensome regulation of these medical products creates uncertainty in the future of innovation and patient care.” ....

Larry-buchson , Diana-degette , Verifying-accurate , Bioworld-medtech , Valid-act , Oldts , Lab-developed-tests , Final-rule , Regulatory , Fda , Us